Michael B. Atkins, MD
Lombardi Comprehensive Cancer Center
Professor of Oncology and Medicine,
Georgetown University Medical Center-
Washington, DC
Arie Belldegrun, MD
David Geffen School of Medicine
at UCLA
Los Angeles, California
Steven Campbell, MD
Cleveland Clinic Foundation
Cleveland, Ohio
Toni K. Choueiri, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Janice P. Dutcher, MD
Associate Director, Cancer Research
Foundation of New York
Chappaqua, New York
Timothy Eisen, MD
University of Cambridge
Department of Oncology,
Addenbrooke's Hospital
Cambridge, UK
Paul Elson, PhD
Cleveland Clinic Foundation
Cleveland, Ohio
72 Kidney Cancer Journal
Bernard Escudier, MD
Institut Gustave-Roussy
Villejuif, France
James H. Finke, PhD
Cleveland Clinic Lerner College of
Medicine of Case Western Reserve
University
Cleveland, Ohio
Keith T. Flaherty, MD
Lecturer, Department of Medicine,
Harvard Medical School
Director of Developmental Therapeutics,
Cancer Center
Massachusetts General Hospital
Boston, Massachusetts
Daniel J. George, MD
Duke Clinical Research Institute
Durham, North Carolina
Inderbir S. Gill, MD
USC Institute of Urology
University of Southern California
Los Angeles, California
Martin Gore, MD
Royal Marsden Hospital
London, UK
Gary Hudes, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Thomas Hutson, DO, PharmD
Baylor University Medical Center
Dallas, Texas
Eugene D. Kwon, MD
Mayo Clinic
Rochester, Minnesota
Bradley C. Leibovich, MD
Mayo Clinic
Rochester, Minnesota
David Nanus, MD
New York Presbyterian Hospital-
Weill Cornell Medical Center
New York, New York
Leslie Oleksowicz, MD
College of Medicine
University of Cincinnati
Medical Center
Cincinnati, Ohio
Allan Pantuck, MD
David Geffen School of Medicine
at UCLA
Los Angeles, California
W. Kimryn Rathmell, MD, PhD
Director, Division of Hematology
Oncology
Professor, Department of Clinical
Medicine and Cancer Biology
Vanderbilt University
Nashville, Tennessee
Brian Rini, MD
Cleveland Clinic Foundation
Cleveland, Ohio
Paul Russo, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York
Ihor S. Sawczuk, MD
Hackensack University
Medical Center
Hackensack, New Jersey
Domenic A. Sica, MD
Medical College of Virginia
Richmond, Virginia
Jeffrey A. Sosman, MD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Nicholas J. Vogelzang, MD
Comprehensive Cancer Centers
of Nevada
Las Vegas, Nevada
EDITORIAL ADVISORY BOARD
Kidney Cancer Journal Author Guidelines
Scope of Manuscripts
The Kidney Cancer Journal considers the following types of manuscripts
for publication:
• Reviews that summarize and synthesize peer-reviewed
literature to date on relevant topics in a scholarly fashion and
format.
• Original contributions based on original, basic, clinical,
translational, epidemiological, or prevention studies relating to
kidney cancer that are well documented, novel, and
significant.
• Letters to the Editor on timely and relevant subjects pertaining to
the diagnosis and treatment of renal cell carcinoma.
• Clinical case studies.
Manuscript Submission
Authors are required to submit their manuscripts in an electronic format,
preferably by email to the Editor-in-Chief, Robert A. Figlin, MD, at
robert.figlin@cshs.org. Please provide in a word processing program.
Images should be submitted electronically as well.
All material reproduced from previously published, copyrighted
material should contain a full credit line acknowledging the original
source. The author is responsible for obtaining this permission.
Contact information
List all authors, including mailing address, titles and affiliations, phone,
fax, and email. Please note corresponding author.
Peer Review and Editing
Manuscripts will be peer reviewed. Accepted manuscripts will be
edited for clarity, spelling, punctuation, grammar, and consistency
with American Medical Association (AMA) style. Authors whose
manuscripts are not initially accepted may have the opportunity
to revise the manuscript based on recommendations from peer
reviewers and at the discretion of the Editor-in-Chief.
Conflict of Interest
Kidney Cancer Journal policy requires that authors reveal to the
Editor-in-Chief any relationships that they believe could be construed
as resulting in an actual, potential, or apparent conflict of interest
with regard to the manuscript submitted for review. Authors must
disclose this information in the covering letter accompanying their
submission.
Manuscript Preparation
Length: Full-length manuscripts should not exceed 4000 words,
including references. Please limit the reference list to 50 citations.
Manuscripts should be accompanied by figures and/or tables. Generally
4-5 figures and 2-3 tables are preferred for each manuscript.
Please include a brief description to accompany these items, as well as
a legend for all abbreviations. Manuscripts should not contain an abstract
but an introduction is recommended.
Spacing: One space after periods. Manuscripts should be double
spaced.
References
All submissions should have references that are referred to in the text
by superscripted numbers and that conform to AMA style.
Example:
Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically
treated patients with chronic pulmonary embolism. Chest.
2001;119:818-823.
Copyright
Manuscripts and accompanying material are accepted for exclusive
publication in the Kidney Cancer Journal. None of the contents may
be reproduced without permission of the Kidney Cancer Journal. To request
permission, please contact Stu Chapman, Executive Editor, (516)
356-5006; email: stulink@aol.com.
link
link